Cardiol Therapeutics Announces Pricing Of $13.5M Public Offering Of 8,437,500 Common Shares At A Price Of $1.60/Share
Cardiol Therapeutics Announces Pricing Of $13.5M Public Offering Of 8,437,500 Common Shares At A Price Of $1.60/Share
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.
Cardiol Therapeutics Inc.（納斯達克:CRDL）（TSX:CRDL）（"Cardiol"或"公司"），一家臨床階段的生命科學公司，專注於心髒病治療的研究和臨床開發抗炎和抗纖維化療法，今日宣佈其先前宣佈的公開發行（"發行"）Opt 8,437,500 股公司的A類普通股（"普通股"），每股普通股以1.60美元的價格對公衆發行，募集資金淨額爲1350萬美元，扣除承銷折讓和佣金以及與發行相關的預計開支。
The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.
公司擬利用此次發行的淨收益支持CardiolRx用於治療複發性心包炎的臨床開發，以及一般和行政開支、營運資本和其他支出。
Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.
Canaccord Genuity將擔任發行的唯一包銷商。
譯文內容由第三人軟體翻譯。
